首页> 中文期刊> 《应用化工》 >羧甲基壳聚糖/海藻酸钠复合止血微球制备工艺研究

羧甲基壳聚糖/海藻酸钠复合止血微球制备工艺研究

         

摘要

The composite hemostatic microspheres of carboxymethyl chitosan/sodium alginate were pre-pared by an emulsion cross-linking method with carboxymethyl chitosan/sodium alginate as the raw mate-rials and glutaraldehyde and calcium chloride as the composite crosslinkers.The factors influencing the preparation of composite hemostatic microspheres were investigated by single factor test with the swelling ratio as an index.On the basis of single factor test results,the experiments were designed by Box-Behnken and the preparation process of the composite hemostatic microspheres was optimized by response surface methodology(RSM).The results indicated that the optimum process conditions were obtained as follows:mass ratio of carboxymethyl chitosan and sodium alginate 1:1,volume of 5% calcium chloride 8 mL,and concentration of the emulsifier 2%.The composite hemostatic microspheres were prepared under the opti-mal conditions and the swelling ratio of the microspheres reached 302.62%.The hemostatic activity in vitro demonstrated that the composite microspheres possessed significant procoagulant capacity.%采用羧甲基壳聚糖和海藻酸钠为基质原料,以戊二醛与氯化钙为复合交联剂,采用乳化交联法制备复合止血微球.以其溶胀率为指标,通过单因素实验研究复合止血微球制备的影响因素;基于单因素实验结果,采用Box-Behnken响应面法(RSM)优化制备工艺.结果表明,复合微球的最佳工艺条件为:羧甲基壳聚糖/海藻酸钠质量比为1:1,5%氯化钙8 mL,乳化剂Span-80浓度2%.在此条件下,复合微球的溶胀率为302.62%,具有显著的体外促凝血活性.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号